IP Library › Granted Patent US 9,115,114
Granted Patent B2
US 9,115,114 · App. 14/658,048 · Granted Aug 25, 2015

Bromodomain inhibitors

Inventors: Michael John Bennett (San Diego, CA); Jeffrey Alan Stafford (San Diego, CA)
Assignee: QUANTICEL PHARMACEUTICALS, INC.
C07D401/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,115,114
App. No.
14/658,048
Granted
Aug 25, 2015
Kind
B2
Abstract

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

Claims (62)

1. A compound of Formula (IIa), or a pharmaceutically acceptable salt thereof,

wherein,

R 2 is CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;

X6 is C—H;

X5 is C—R 5 ;

R 5 is hydrogen, halogen, —OH, —CN, —OR 61 , —NHR 61 , —N(R 61 ) 2 , alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, wherein each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

R 6 is hydrogen, halogen, —OH, —CN, alkyl, cycloalkyl, cycloalkylalkyl, amino, alkylamino, dialkylamino, cycloalkylalkylamino, alkoxy, or cycloalkylalkoxy;

R A is

X2 is N;

R 13 is —Y—Z;

Y is selected from a bond, or —CH 2 —;

Z is selected from —SO 2 R 21 , —N(R 22 )SO 2 R 21 , —SO 2 N(R 22 ) 2 , —N(R 22 )SO 2 N(R 22 ) 2 , —CON(R 22 ) 2 , —N(R 22 )CO 2 R 21 , —N(R 22 )CON(R 22 ) 2 , —N(R 22 )COR 21 , —OC(O)N(R 22 ) 2 , —OSO 2 N(R 22 ) 2 , or —N(R 22 )SO 3 R 21 ;

X3 is N;

X4 is C—R 15 , wherein R 15 is hydrogen, halogen, —CN, alkyl, or alkoxy;

R 16 is hydrogen, halogen, or —W—X, wherein W is a bond, —O—, —S—, or —NH—, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; and

each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen, halogen, —OR 61 , or alkyl; R 61 is alkyl; and R 6 is hydrogen, halogen, alkyl, alkoxy.

3. The compound of claim 2 having the structure of Formula (IIb), or a pharmaceutically acceptable salt thereof,

wherein,

R 2 is CH 3 ;

X6 is C—H;

X5 is C—R 5 ;

R 5 is hydrogen;

R 6 is halogen or alkyl;

R A is

X2 is N;

R 13 is —Y—Z;

Y is selected from a bond, or —CH 2 —;

Z is selected from —SO 2 R 21 , —N(R 22 )SO 2 R 21 , —SO 2 N(R 22 ) 2 , —N(R 22 )SO 2 N(R 22 ) 2 , —CON(R 22 ) 2 , —N(R 22 )CO 2 R 21 , —N(R 22 )CON(R 22 ) 2 , —N(R 22 )COR 21 , —OC(O)N(R 22 ) 2 , —OSO 2 N(R 22 ) 2 , or —N(R 22 )SO 3 R 21 ;

X3 is N;

X4 is C—R 15 , wherein R 15 is hydrogen, halogen, —CN, alkyl, or alkoxy;

R 16 is —W—X, wherein W is a bond, —O—, —S—, or —NH—, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;

each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; and

each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.

4. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 6 is halogen.

5. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 6 is alkyl.

6. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 6 is C 1 -C 3 alkyl.

7. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 6 is C 1 alkyl.

8. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Y is a bond.

9. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Y is a —CH 2 —.

10. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Z is —SO 2 R 21 .

11. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Z is —N(R 22 )SO 2 R 21 .

12. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl.

13. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 21 is alkyl.

14. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 21 is C 1 -C 2 alkyl.

15. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 22 is hydrogen.

16. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is —O—.

17. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is a bond.

18. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X is alkyl.

19. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X is aryl.

20. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X is cycloalkylalkyl.

21. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is —O— and X is aryl.

22. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is —O— and X is cycloalkylalkyl.

23. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is a bond and X is alkyl.

24. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein W is a bond and X is cycloalkylalkyl.

25. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

26. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

27. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

28. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

29. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, having the structure of:

30. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (IIa) as described in claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2016
From: QUANTICEL PHARMACEUTICALS, INC.
To: CELGENE QUANTICEL RESEARCH, INC.
Reel/Frame 038399/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2015
From: BENNETT, MICHAEL JOHN; STAFFORD, JEFFREY ALAN
To: QUANTICEL PHARMACEUTICALS, INC.
Reel/Frame 035361/0268 →
Continuity (4)
Continuation 14517705 · Oct 17, 2014
Provisional Application 61931467 · Jan 24, 2014
Provisional Application 61893133 · Oct 18, 2013
Related Publication 20150183784A1 · Jul 2, 2015